MBCOF (Marvel Biosciences) Debt-to-Equity: -0.51 (As of Apr. 2026)


MBCOF Marvel Biosciences Corp MBCOF
34 GF Score
Price $0.11
! 1 Warning Sign
View Full Analysis

What is Marvel Biosciences Debt-to-Equity?

Marvel Biosciences MBCOF 34 Debt-to-Equity is -0.51 as of Apr. 2026. GuruFocus rates MBCOF with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 965 Biotechnology companies, Marvel Biosciences ranks worse than 103626.84% on this metric.

Marvel Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Apr. 2026 was $0.56 Mil. Marvel Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Apr. 2026 was $0.45 Mil. Marvel Biosciences's Total Stockholders Equity for the quarter that ended in Apr. 2026 was $-1.99 Mil. Marvel Biosciences's debt to equity for the quarter that ended in Apr. 2026 was -0.51.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Marvel Biosciences's Debt-to-Equity or its related term are showing as below:

MBCOF' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.61   Med: -0.58   Max: -0.45
Current: -0.51

During the past 6 years, the highest Debt-to-Equity Ratio of Marvel Biosciences was -0.45. The lowest was -1.61. And the median was -0.58.

MBCOF's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.16 vs MBCOF: -0.51

Marvel Biosciences  (OTCPK:MBCOF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Marvel Biosciences Debt-to-Equity Related Terms

Marvel Biosciences Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Marvel Biosciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marvel Biosciences Debt-to-Equity Chart

Marvel Biosciences Annual Data
Trend Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Debt-to-Equity
Get a 7-Day Free Trial 0.00 0.00 -0.58 -0.61 -0.58

Marvel Biosciences Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.58 -0.58 -0.63 -0.60 -0.51

MBCOF vs VRTX, REGN, ALNY: Debt-to-Equity Comparison

For the Biotechnology subindustry, Marvel Biosciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Marvel Biosciences Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marvel Biosciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Marvel Biosciences's Debt-to-Equity falls into.


MBCOF
34GF Score
Marvel Biosciences Corp MBCOF
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Marvel Biosciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Marvel Biosciences's Debt to Equity Ratio for the fiscal year that ended in Jul. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(1.687 + 0) / -2.926
=-0.58

Marvel Biosciences's Debt to Equity Ratio for the quarter that ended in Apr. 2026 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.561 + 0.454) / -1.988
=-0.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of -0.51 mean?
Marvel Biosciences (MBCOF) has a Debt-to-Equity of -0.51 as of Apr. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Marvel Biosciences and its competitors. According to the industry distribution chart, Marvel Biosciences ranks #999999 out of 965 companies in the Biotechnology industry.
Is Marvel Biosciences' Debt-to-Equity too high?
Marvel Biosciences' current Debt-to-Equity is -0.51. Based on the distribution chart, Marvel Biosciences ranks #999999 out of 965 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Marvel Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Marvel Biosciences' Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Marvel Biosciences ranks #999999 out of 965 companies for Debt-to-Equity. This places Marvel Biosciences in the lower half of its industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Marvel Biosciences and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Marvel Biosciences's current Debt-to-Equity is -0.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marvel Biosciences stock overvalued right now?
Marvel Biosciences (MBCOF) has a current Debt-to-Equity of -0.51. The current Debt-to-Equity is -0.51. Marvel Biosciences' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Marvel Biosciences (MBCOF), the current Debt-to-Equity is -0.51 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Marvel Biosciences Business Description

Other Exchanges MRVL:Canada
Address 505 - 8th Avenue SW, Suite 420, Calgary, AB, CAN, T2P1G2
Marvel Biosciences Corp is a biotechnology company incorporated in Canada. The Company is currently a pre-clinical stage pharmaceutical development company that utilizes a drug redevelopment approach to identify and evaluate potential therapeutic compounds. Its activities mainly involve scientific research and pre-clinical studies aimed at determining viable active compounds for further drug development.
34GF Score

Get the complete analysis for MBCOF

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.11
Price